论文部分内容阅读
目的观察白细胞介素-2(IL-2)基因转染联合特异性细胞毒性 T 淋巴细胞(sCTL)治疗裸鼠肝癌的疗效。方法荷肝癌裸鼠6只,随机分为 pORF-hIL-2质粒转染实验组和对照组,检测血浆白细胞介素(IL)-2的浓度。荷肝癌裸鼠24只,随机分成对照组、IL-2基因治疗组、sCTL治疗组和 IL-2基因联合 sCTL 治疗组,观察肿瘤体积变化及生存时间。结果实验组血清 IL-2浓度在转染后第3天到达顶峰135.3 ng/L,持续15 d,对照组检测不到 IL-2;各组肿瘤体积(治疗15 d后)变化为(262.27±78.30)、(151.65±63.93)、(27.16±27.69)、(-63.32±16.92)mm~;中位生存时间20、27.5、60、90 d;差异均有统计学意义(P<0.01)。结论联合应用 IL-2基因转染和 sCTL细胞治疗裸鼠的 HepG2移植瘤,可以明显地提高抗瘤效应,表现协同增效作用。
Objective To observe the efficacy of interleukin-2 (IL-2) gene transfection combined with specific cytotoxic T lymphocytes (sCTL) in the treatment of hepatocellular carcinoma in nude mice. Methods Six nude mice bearing hepatoma were randomly divided into experimental group and control group transfected with pORF-hIL-2 plasmid, and the plasma concentration of interleukin-2 was detected. Twenty-four hepatocellular carcinoma nude mice were randomly divided into control group, IL-2 gene therapy group, sCTL treatment group and IL-2 gene combined with sCTL treatment group. The tumor volume change and survival time were observed. Results The serum IL-2 level of the experimental group reached a peak of 135.3 ng / L on the third day after transfection for 15 days, but no IL-2 was detected in the control group. The tumor volume in each group changed 262.27 ± 78.30), (151.65 ± 63.93), (27.16 ± 27.69) and (-63.32 ± 16.92) mm ~; respectively. The median survival time was 20, 27.5, 60 and 90 days. There were significant differences between the two groups (P <0.01). Conclusion The combined application of IL-2 gene transfection and sCTL cells in HepG2 xenografts in nude mice can significantly improve the anti-tumor effect and show a synergistic effect.